KR20250099279A - 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 - Google Patents

비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 Download PDF

Info

Publication number
KR20250099279A
KR20250099279A KR1020257020887A KR20257020887A KR20250099279A KR 20250099279 A KR20250099279 A KR 20250099279A KR 1020257020887 A KR1020257020887 A KR 1020257020887A KR 20257020887 A KR20257020887 A KR 20257020887A KR 20250099279 A KR20250099279 A KR 20250099279A
Authority
KR
South Korea
Prior art keywords
antibody
fgfr2iiib
amino acid
ser
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257020887A
Other languages
English (en)
Korean (ko)
Inventor
토머스 하딩
크리스틴 피어스
남라타 파틸
토머스 브레넌
줄리 햄블턴
Original Assignee
파이브 프라임 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20250099279(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 파이브 프라임 테라퓨틱스, 인크. filed Critical 파이브 프라임 테라퓨틱스, 인크.
Publication of KR20250099279A publication Critical patent/KR20250099279A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257020887A 2013-08-01 2014-07-31 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 Pending KR20250099279A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361861198P 2013-08-01 2013-08-01
US61/861,198 2013-08-01
US201361901732P 2013-11-08 2013-11-08
US61/901,732 2013-11-08
US201461933632P 2014-01-30 2014-01-30
US61/933,632 2014-01-30
KR1020237010509A KR102825701B1 (ko) 2013-08-01 2014-07-31 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체
PCT/US2014/049008 WO2015017600A1 (en) 2013-08-01 2014-07-31 Afucosylated anti-fgfr2iiib antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010509A Division KR102825701B1 (ko) 2013-08-01 2014-07-31 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체

Publications (1)

Publication Number Publication Date
KR20250099279A true KR20250099279A (ko) 2025-07-01

Family

ID=51358085

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237010509A Active KR102825701B1 (ko) 2013-08-01 2014-07-31 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체
KR1020167005003A Active KR102516152B1 (ko) 2013-08-01 2014-07-31 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체
KR1020257020887A Pending KR20250099279A (ko) 2013-08-01 2014-07-31 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020237010509A Active KR102825701B1 (ko) 2013-08-01 2014-07-31 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체
KR1020167005003A Active KR102516152B1 (ko) 2013-08-01 2014-07-31 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체

Country Status (30)

Country Link
US (5) US20150050273A1 (enExample)
EP (3) EP3708583B1 (enExample)
JP (5) JP6860342B2 (enExample)
KR (3) KR102825701B1 (enExample)
CN (2) CN112225810B (enExample)
AU (4) AU2014296174B2 (enExample)
CA (1) CA2915665C (enExample)
CL (2) CL2016000221A1 (enExample)
CY (2) CY1121517T1 (enExample)
DK (2) DK3027651T3 (enExample)
ES (2) ES2913291T3 (enExample)
HR (1) HRP20190502T1 (enExample)
HU (2) HUE043815T2 (enExample)
IL (1) IL243409B (enExample)
LT (2) LT3027651T (enExample)
ME (1) ME03476B (enExample)
MX (2) MX374785B (enExample)
MY (1) MY184628A (enExample)
NZ (1) NZ715201A (enExample)
PE (2) PE20210949A1 (enExample)
PH (3) PH12019501393B1 (enExample)
PL (2) PL3027651T3 (enExample)
PT (2) PT3027651T (enExample)
RS (1) RS58719B1 (enExample)
RU (2) RU2698061C2 (enExample)
SG (1) SG11201600767UA (enExample)
SI (2) SI3708583T1 (enExample)
TW (2) TWI679021B (enExample)
WO (1) WO2015017600A1 (enExample)
ZA (1) ZA201603218B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12019501393B1 (en) * 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
WO2015067547A1 (en) * 2013-11-05 2015-05-14 Roche Diagnostics Gmbh A method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto
EP3287522A4 (en) * 2015-04-20 2019-03-27 Daiichi Sankyo Company, Limited DETECTION OF FGFR2
CN108368174B (zh) * 2015-11-23 2023-04-14 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
BR112019023898A2 (pt) * 2017-05-16 2020-06-09 Five Prime Therapeutics Inc método para tratamento de câncer gástrico, uso de um anticorpo e composição
EP3625256A1 (en) 2017-05-19 2020-03-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
PE20200797A1 (es) 2017-08-25 2020-08-10 Five Prime Therapeutics Inc Anticuerpos que se unen especificamente a b7-h4 humana
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
SG11202007820QA (en) 2018-02-21 2020-09-29 Five Prime Therapeutics Inc B7-h4 antibody dosing regimens
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
WO2020072896A1 (en) * 2018-10-05 2020-04-09 Five Prime Therapeutics, Inc. Anti-fgfr2 antibody formulations
BR112021007134A2 (pt) 2018-10-15 2021-08-10 Five Prime Therapeutics, Inc. terapia combinada para câncer
CA3160811A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
AR120883A1 (es) * 2019-12-24 2022-03-23 Dizal Jiangsu Pharmaceutical Co Ltd Anticuerpos anti-fgfr2b
AR120886A1 (es) * 2019-12-24 2022-03-30 Dizal Jiangsu Pharmaceutical Co Ltd Anticuerpos anti-fgfr2b
IL295979A (en) 2020-03-06 2022-10-01 Ona Therapeutics S L Anti-cd36 antibodies and their use for cancer treatment
JP7767411B2 (ja) * 2020-10-22 2025-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｆｇｆｒ２抗体及びその使用方法
US20240101683A1 (en) * 2020-12-29 2024-03-28 Shenzhen Forward Pharmaceuticals Co., Limited Anti-FGFR2 Antibody and Use Thereof
CN118488964A (zh) 2021-07-30 2024-08-13 Ona疗法有限公司 抗cd36抗体及其治疗癌症的用途
US20250277041A1 (en) * 2021-10-08 2025-09-04 Shenzhen Forward Pharmaceuticals Co., Limited Anti-fgfr2 adcc enhanced antibody and use thereof
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
WO2024067876A1 (en) * 2022-09-30 2024-04-04 3H Pharmaceuticals Co., Ltd. Anti-fgfr2b antibodies and uses thereof
CN117917435A (zh) * 2022-10-21 2024-04-23 北京天广实生物技术股份有限公司 结合fgfr2b的抗体及其用途
TW202442679A (zh) * 2022-12-28 2024-11-01 大陸商蘇州創勝醫藥集團有限公司 抗－ｆｇｆｒ２ｂ抗體及其用途
TW202442685A (zh) * 2023-04-28 2024-11-01 大陸商武漢人福創新藥物研發中心有限公司 抗FGFR2b單抗
WO2025103358A1 (en) * 2023-11-14 2025-05-22 Suzhou Transcenta Therapeutics Co., Ltd. Anti-fgfr2b immunoconjugates and their use in the treatment of cancer
WO2025130860A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体及其应用
WO2025232811A1 (zh) * 2024-05-09 2025-11-13 正大天晴药业集团股份有限公司 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DK0481000T3 (da) 1989-07-06 1999-11-15 Univ California Receptorer for fibroblastvækstfaktorer
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
EP1125584A4 (en) 1998-10-30 2005-01-12 Takeda Chemical Industries Ltd PREPARATIONS CONTAINING BETACELLULIN PROTEIN
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
EP1331266B1 (en) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP2005500034A (ja) 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
CN101357943A (zh) * 2001-10-25 2009-02-04 杰南技术公司 糖蛋白组合物
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003063893A2 (en) 2002-01-31 2003-08-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fgfr agonists
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT CONTAINING ANTIBODY COMPOSITION
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
JPWO2003085119A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
KR100493460B1 (ko) 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
KR100973564B1 (ko) * 2003-05-02 2010-08-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk COMPOSITION OF CONDENSED PROTEINS
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
EP1680140B1 (en) * 2003-10-16 2011-04-20 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
EP2330201B1 (en) 2003-10-22 2017-04-05 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
JP4653109B2 (ja) 2003-11-05 2011-03-16 ロシュ グリクアート アクチェンゲゼルシャフト 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CA2550245A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
EP1773305A2 (en) 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
CA2589895A1 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
ES2498794T3 (es) * 2005-02-18 2014-09-25 Medarex, L.L.C. Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
CA2648021A1 (en) 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
WO2007134210A2 (en) 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
WO2007146847A2 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
WO2008052796A1 (en) 2006-11-03 2008-05-08 U3 Pharma Gmbh Fgfr4 antibodies
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
US20090068110A1 (en) 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
ES2538990T3 (es) 2007-01-24 2015-06-25 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo genéticamente recombinante que tiene una actividad efectora mejorada
AU2008230880B2 (en) 2007-03-23 2014-04-24 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
EP2142569A2 (en) * 2007-03-28 2010-01-13 Biogen Idec, Inc. Non-fucosylated antibodies
EP2205277B1 (en) 2007-10-22 2017-07-26 Genmab A/S Novel antibody therapies
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
WO2009119173A1 (ja) 2008-03-26 2009-10-01 日本電気株式会社 無線リソースの制御方法、無線局装置、無線局制御プログラムを格納した記録媒体、及び無線通信システム
WO2009151448A1 (en) * 2008-06-10 2009-12-17 University Of Southern California Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
DK2365828T3 (en) 2008-11-07 2014-12-08 Galaxy Biotech Llc Monoclonal antibodies against fibroblast second
WO2011025814A1 (en) 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury
CA2776385C (en) * 2009-10-07 2019-04-09 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
JP2013508292A (ja) * 2009-10-14 2013-03-07 カロバイオス ファーマシューティカルズ インコーポレイティッド ＥｐｈＡ３に対する抗体
BR112012016992A2 (pt) 2010-01-14 2019-09-24 Univ Yale "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena".
WO2011115937A1 (en) 2010-03-14 2011-09-22 The Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
US8481688B2 (en) 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2603521A4 (en) 2010-08-12 2014-10-01 Attogen Inc ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
EP3828205A1 (en) * 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
ES2704038T3 (es) 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013087716A2 (de) 2011-12-14 2013-06-20 Bayer Pharma Aktiengesellschaft Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
PT2831110T (pt) * 2012-03-30 2018-09-28 Univ California Terapia anti-emp2 reduz as células-tronco do cancro
NZ631445A (en) 2012-04-09 2017-02-24 Daiichi Sankyo Co Ltd Anti-fgfr2 antibody
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN104619840A (zh) 2012-07-05 2015-05-13 日本国立癌症研究中心 Fgfr2融合基因
WO2014089193A1 (en) 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
AU2014207342C1 (en) 2013-01-18 2019-04-04 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US20160067307A1 (en) 2013-05-01 2016-03-10 Five Prime Therapeutics, Inc. Methods of treating cancer
EP3800266A1 (en) 2013-06-13 2021-04-07 University Of South Australia Methods for detecting prostate cancer
PH12019501393B1 (en) * 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170175197A1 (en) 2014-01-29 2017-06-22 Caris Mpi, Inc. Molecular profiling of immune modulators
JP6877350B2 (ja) 2014-11-05 2021-05-26 ジェネンテック， インコーポレイテッド 抗ｆｇｆｒ２／３抗体及びその使用方法
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN108368174B (zh) 2015-11-23 2023-04-14 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
BR112019023898A2 (pt) 2017-05-16 2020-06-09 Five Prime Therapeutics Inc método para tratamento de câncer gástrico, uso de um anticorpo e composição

Also Published As

Publication number Publication date
US20250269016A1 (en) 2025-08-28
PL3027651T3 (pl) 2019-08-30
AU2025203545A1 (en) 2025-06-05
RU2740714C2 (ru) 2021-01-20
NZ715201A (en) 2021-12-24
PE20210949A1 (es) 2021-05-24
RS58719B1 (sr) 2019-06-28
KR102516152B1 (ko) 2023-03-31
DK3027651T3 (en) 2019-04-15
JP2016527273A (ja) 2016-09-08
IL243409B (en) 2019-10-31
ZA201603218B (en) 2019-03-27
US20220168416A1 (en) 2022-06-02
AU2021245169A1 (en) 2021-11-04
US20150050273A1 (en) 2015-02-19
CY1125443T1 (el) 2024-12-13
RU2016106101A (ru) 2017-09-06
PH12021552742A1 (en) 2022-05-23
KR20160030578A (ko) 2016-03-18
LT3708583T (lt) 2022-04-11
EP4036118A1 (en) 2022-08-03
JP6860342B2 (ja) 2021-04-14
KR20230047508A (ko) 2023-04-07
CN105452296A (zh) 2016-03-30
SI3708583T1 (sl) 2022-05-31
SG11201600767UA (en) 2016-03-30
US20160339100A1 (en) 2016-11-24
PE20160190A1 (es) 2016-04-28
TW201536804A (zh) 2015-10-01
JP2023018049A (ja) 2023-02-07
TW201906629A (zh) 2019-02-16
US10172937B2 (en) 2019-01-08
JP2020040955A (ja) 2020-03-19
BR112015032789A2 (pt) 2017-11-07
CL2018002291A1 (es) 2018-09-14
SI3027651T1 (sl) 2019-05-31
US12465636B2 (en) 2025-11-11
LT3027651T (lt) 2019-04-10
EP3027651B1 (en) 2019-02-27
PH12019501393A1 (en) 2020-09-14
HUE058243T2 (hu) 2022-07-28
IL243409A0 (en) 2016-03-31
PT3708583T (pt) 2022-05-13
CN112225810B (zh) 2024-10-29
EP3027651A1 (en) 2016-06-08
HUE043815T2 (hu) 2019-09-30
TWI633120B (zh) 2018-08-21
CA2915665C (en) 2020-07-28
CL2016000221A1 (es) 2016-07-08
AU2019206039B2 (en) 2021-07-08
TWI679021B (zh) 2019-12-11
AU2014296174B2 (en) 2019-05-02
PH12016500137A1 (en) 2016-04-18
CN105452296B (zh) 2020-09-25
PH12019501393B1 (en) 2022-09-07
RU2019125027A3 (enExample) 2020-02-28
RU2019125027A (ru) 2019-08-19
JP2025118617A (ja) 2025-08-13
HRP20190502T1 (hr) 2019-05-03
CA2915665A1 (en) 2015-02-05
AU2019206039A1 (en) 2019-08-01
EP3708583A1 (en) 2020-09-16
ME03476B (me) 2020-01-20
PL3708583T3 (pl) 2022-06-06
ES2719103T3 (es) 2019-07-08
AU2021245169B2 (en) 2025-02-20
AU2014296174A1 (en) 2016-01-21
EP3708583B1 (en) 2022-03-02
PH12016500137B1 (en) 2019-12-04
JP7183136B2 (ja) 2022-12-05
MX2016001236A (es) 2016-05-24
RU2698061C2 (ru) 2019-08-21
US20190175730A1 (en) 2019-06-13
WO2015017600A1 (en) 2015-02-05
MX2020009223A (es) 2020-10-14
ES2913291T3 (es) 2022-06-01
MX374785B (es) 2025-03-06
MY184628A (en) 2021-04-10
PT3027651T (pt) 2019-05-31
KR102825701B1 (ko) 2025-06-27
US11235059B2 (en) 2022-02-01
DK3708583T3 (da) 2022-05-16
CN112225810A (zh) 2021-01-15
CY1121517T1 (el) 2020-05-29
JP2022078080A (ja) 2022-05-24
HK1220211A1 (en) 2017-04-28

Similar Documents

Publication Publication Date Title
US12465636B2 (en) Method of making afucosylated anti-FGFR2IIIB antibodies
HK40078300A (en) Afucosylated anti-fgfr2iiib antibodies
HK40036393A (en) Afucosylated anti-fgfr2iiib antibodies
HK40036393B (en) Afucosylated anti-fgfr2iiib antibodies
HK40044506A (en) Afucosylated anti-fgfr2iiib antibodies
HK1220211B (en) Afucosylated anti-fgfr2iiib antibodies
BR112015032789B1 (pt) Composições, método para produzir anticorpos, composições farmacêuticas e uso de uma composição farmacêutica

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250623

Application number text: 1020237010509

Filing date: 20230327

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250701

Comment text: Request for Examination of Application

PG1501 Laying open of application